FORM 3
        	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
	OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

Leonard Frank X	2. Date of Event Requiring Statement (MM/DD/YYYY)
9/1/2020 
	3. Issuer Name and Ticker or Trading Symbol

NovoCure Ltd [NVCR]	
(Last)       (First)       (Middle)

C/O NOVOCURE INC.,, 20 VALLEY STREAM PARKWAY, SUITE 300	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Development Officer /	
(Street)

MALVERN, PA 19355      

(City)             (State)             (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)
 
	6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned	
1.Title of Security
(Instr. 4)	2. Amount of Securities Beneficially Owned
(Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)	4. Nature of Indirect Beneficial Ownership
(Instr. 5)	
Ordinary Shares 	59811 	D 	 	
Restricted Share Units 	1465 (1)	D 	 	
Restricted Share Units 	733 (2)	D 	 	
Restricted Share Units 	5314 (3)	D 	 	
Restricted Share Units 	3001 (4)	D 	 	
Restricted Share Units 	5405 (5)	D 	 	
Restricted Share Units 	5904 (6)	D 	 	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 4)	2. Date Exercisable and Expiration Date
(MM/DD/YYYY)	3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)	6. Nature of Indirect Beneficial Ownership
(Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to Buy Ordinary Shares 	 (7)	2/23/2025 	Ordinary Shares 	14784.0 	$14.37 	D 	 	
Options to Buy Ordinary Shares 	 (7)	2/24/2026 	Ordinary Shares 	15000.0 	$11.46 	D 	 	
Options to Buy Ordinary Shares 	 (8)	2/21/2027 	Ordinary Shares 	19500.0 	$7.15 	D 	 	
Options to Buy Ordinary Shares 	 (9)	2/26/2028 	Ordinary Shares 	32103.0 	$21.15 	D 	 	
Options to Buy Ordinary Shares 	 (10)	7/30/2028 	Ordinary Shares 	16148.0 	$34.0 	D 	 	
Options to Buy Ordinary Shares 	 (11)	3/21/2029 	Ordinary Shares 	14595.0 	$47.04 	D 	 	
Options to Buy Ordinary Shares 	 (12)	7/30/2029 	Ordinary Shares 	7809.0 	$83.3 	D 	 	
Options to Buy Ordinary Shares 	 (13)	3/2/2030 	Ordinary Shares 	10422.0 	$69.37 	D 	 	
Options to Buy Ordinary Shares 	 (14)	8/31/2030 	Ordinary Shares 	11336.0 	$84.68 	D 	 	

Explanation of Responses:	
(1) 	Represents restricted share units that are scheduled to vest on February 27, 2021, subject to the reporting person's continued employment through such date.	
(2) 	Represents restricted share units that are scheduled to vest on July 31, 2021, subject to the reporting person's continued employment through such date.	
(3) 	Represents restricted share units that are scheduled to vest in equal installments on each of March 22, 2021 and 2022, subject to the reporting person's continued employment through such dates.	
(4) 	Represents restricted share units that are scheduled to vest in equal installments on each of July 30, 2021 and 2022, subject to the reporting person's continued employment through such dates.	
(5) 	Represents restricted share units that are scheduled to vest in equal installments on each of March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.	
(6) 	Represents restricted share units that are scheduled to vest in equal installments on each of September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.	
(7) 	Currently exercisable.	
(8) 	Options to buy 19,500 ordinary shares, 13,000 shares of which are currently exercisable and the remainder vest on February 22, 2021.	
(9) 	Options to buy 32,103 ordinary shares, 16,052 shares of which are currently exercisable and the remaining 16,061 shares of which will vest and become exercisable in equal installments on each of February 27, 2021 and 2022, subject to the reporting person's continued employment through such dates.	
(10) 	Options to buy 16,148 ordinary shares, 8,074 shares of which are currently exercisable and the remaining 8,074 shares of which will vest and become exercisable in equal installments on each of July 31, 2021 and 2022, subject to the reporting person's continued employment through such dates.	
(11) 	Options to buy 14,595 ordinary shares, 3,649 shares of which are currently exercisable and the remaining 10,946 shares will vest and become exercisable in equal installments on each of March 22, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.	
(12) 	Options to buy 7,809 ordinary shares, 1,953 shares of which are currently exercisable and the remaining 5,856 shares of which will vest and become exercisable in equal installments on each of July 30, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.	
(13) 	Options to buy 10, 422 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.	
(14) 	Options to buy 11,336 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
Leonard Frank X
C/O NOVOCURE INC.,
20 VALLEY STREAM PARKWAY, SUITE 300
MALVERN, PA 19355			Chief Development Officer		

Signatures		
By: /s/ Steven Robbins, Attorney in Fact for Frank X. Leonard		9/10/2020	
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.